中山痔疮做手术几天能好(中山肚子右边疼是怎么回事) (今日更新中)

BEIJING, Sept. 1 (Xinhua) -- Chinese scientists have decided to reschedule the launch of the Tiangong-1, an unmanned space module, due to the failed launch of an experimental orbiter, a spokesperson with the project said Thursday.The decision to delay the launch was based on the consideration that the carrier rocket Long-March II-F, which would be used for the upcoming launch, belongs to the same series as the malfunctioning one that led to the experimental orbiter SJ-11-04 failing to enter Earth's orbit in August."As the investigation into the malfunction of the rocket Long-March II-C remains underway, it is not clear yet whether the malfunction is linked with the Long-March II-F," the unnamed spokesperson said.Previously, the Long-March II-F was expected to send the 8.5-metric ton Tiangong-1, or "Heavenly Palace 1," into space in the second half of this year to perform the nation's first space-docking procedure.The Tiangong-1 will dock with the unmanned Shenzhou-8 spacecraft, which will be sent into space after the Tiangong-1's launch."The specific launch date for the Tiangong-1 will be set based on the results of the investigation into the malfunctioning rocket," the spokesperson said, adding that the project's teams are currently double-checking every product that will be involved in the space-docking.The Shenzhou-8 spacecraft, the Long March II-F carrier rocket, and the Tiangong-1 have all been transferred to the Jiuquan Satellite Launch Center in northwest China's Gansu Province, the spokesperson said.

SAN FRANCISCO, Sept. 13 (Xinhua) -- Researchers in San Francisco, U.S. have found in a latest study that bisphenol A (BPA) and methylparaben, two chemicals commonly used in consumer products, can interfere with the breast cancer drugs, local media reported on Tuesday.In the study, doctors from California Pacific Medical Center in San Francisco found that healthy breast cells from high-risk patients started to find ways to bypass breast cancer drugs after they were exposed to BPA and methylparaben in the lab.The cells exposed to the two chemicals kept growing and didn't die after they were introduced with Tamoxifen, a current standard drug therapy for female breast cancer and most common used treatment for male breast cancer, Dr. William Goodson, lead author of the study, told San Francisco Chronicle.Goodson said that BPA and methylparaben not only mimic estrogen 's ability to drive cancer, but appear to be even better than the natural hormone in bypassing the ability of drugs to treat it. The finds have been published online in the British medical journal Carcinogenesis.The research shows more evidence of safety issues of BPA, a chemical primarily used to make plastic baby bottles, food containers, household electronics and etc, as well as the less known methylparaben, a chemical preservative used in cosmetics and other personal care products.The researchers noted that the breast cancer rates have been growing by about the same amount in men as in women over the past three decades. Scientists have been looking at environmental causes for the disease and wondering where the hormones are coming from.Goodson said BPA and methylparaben are used so widely and even found in household dust, noting that it is still unknown whether the effects of exposure to the chemicals are reversible.Since 2008, several governments issued reports questioning the negative health effects of BPA, especially raising concerns regarding exposure of fetuses, infants and children. BPA use has been banned in baby bottles in a lot of countries and regions.As for methylparaben, the U.S. Food and Drug Administration said on its website that "at the present time there is no reason for consumers to be concerned about the uses of cosmetics containing parabens (including methylparaben)."

WASHINGTON, Aug. 2 (Xinhua) -- A new study has identified the recent emergence of a multidrug-resistant strain of Salmonella that has a high level resistance to ciprofloxacin, a common treatment for severe Salmonella infections. The study was published on-line Tuesday in The Journal of Infectious Diseases.Francois-Xavier Weill at the Pasteur Institute in France and colleagues studied information from national surveillance systems in France, England and Wales, Denmark, and the United States. The data showed that a multidrug-resistant strain of Salmonella, known as S. Kentucky, infected 489 patients in France, England and Wales, and Denmark between 2000 and 2008. In addition, researchers reported that the first infections were acquired mainly in Egypt between 2002 and 2005, while since 2006 the infections have also been acquired in various parts of Africa and the Middle East. The absence of reported international travel in approximately 10 percent of the patients suggests that infections may have also occurred in Europe through consumption of contaminated imported foods or through secondary contaminations.In this study, multidrug-resistant S. Kentucky was isolated from chickens and turkeys from Ethiopia, Morocco, and Nigeria, suggesting that poultry is an important agent for infection. The common use of fluoroquinolones in chicken and turkey production in Nigeria and Morocco may have contributed to this rapid spread, according to the researchers.This study highlights the importance of public health surveillance in a global food system. The investigators reported that they will continue to monitor this multidrug-resistant strain as well as help strengthen the capacities of national and regional laboratories in the surveillance of Salmonella and other major foodborne pathogens through the World Health Organization Global Foodborne Infections Network.Salmonella infection represents a major public health problem worldwide. An estimated 1.7 million such infections occur in North America each year. More than 1.6 million cases were reported between 1999 and 2008 in 27 European countries. Although most Salmonella infections produce only mild gastroenteritis, elderly and immunocompromised patients are especially at risk for life- threatening infections. These cases are typically treated with antimicrobials called fluoroquinolones, such as ciprofloxacin.

BEIJING, Sept. 20 (Xinhuanet)-- Google's executive chairman Eric Schmidt is to face a Senate hearing on whether the company is abusing its dominance in Internet search, according to media reports on Tuesday.At the Wednesday's hearing before the Senate Judiciary Committee's antitrust panel, Schmidt will argue that critics are wrong to say Google gives preference to its own products, instead, Google is just trying to deliver the best-cultivated search results for users. The issue of search ranking is a touchy subject with Google, which says its algorithm is devised to give users the most useful result so they will come back.Another focal point of the hearing, which Schmidt concerned most is "scrapers", those who game its search algorithm, for example, taking commonly searched words, combine them into a nonsensical block of text and throw it up on the Web to grab eyeballs and advertising dollars.Google believes that, if scrapers succeed too often, consumers will lose confidence in search and turn to other resources, thus posing an existential threat to the company.Regulators in the U.S. and abroad have been looking into various aspects of Google's business practices since the company's 2007 purchase of ad firm DoubleClick. At the moment, European regulators are conducting an antitrust inquiry into Google's search business while the Federal Trade Commission is doing likewise. Google relies overwhelmingly on its core product, Internet search, and dominates the market for that product. It handles around two-thirds of U.S. Internet searches and more than 80 percent in many European countries, according to comScore Inc.

WASHINGTON, July 20 (Xinhua) -- The loss of a protein that coats sperm may explain a significant proportion of infertility in men worldwide, according to a study by an international team of researchers led by University of California Davis.A paper describing the work was published Wednesday in the journal Science Translational Medicine. The research could open up new ways to screen and treat couples for infertility.The gene DEFB126 encodes a protein called Beta Defensin 126, which coats the surface of sperm and helps it penetrate cervical mucus in the female. A survey of samples from the U.S., Britain and China showed that as many as a quarter of men worldwide carry two copies of the defective gene.In the new study, researchers found that men with a muted DEFB126 lack Beta Defensin 126, making it much more difficult for sperm to swim through the mucus and eventually join with an egg.Examining 500 newly married Chinese couples, researchers found that the lack of Beta Defensin 126 in men with the DEFB126 mutation lowered fertility (even among men that did not display other deficiencies usually associated with infertility, like inadequate semen volume and low sperm motility). Wives of men with the Beta Defensin 126 variant were significantly less likely to become pregnant than were other couples, and 30 percent less likely to have a birth.This genetic variation in DEFB126 likely accounts for many unexplained cases of infertility, researchers say. They hope next to work with a major infertility program in the U.S. to further explore the role of the mutation.

来源：资阳报